What were Alpek's key financial results for Q2 2024, and how did they compare to analyst expectations and prior periods?

Alpek reported second-quarter adjusted net income of $183 million, reversing from a $29 million loss year over year and a $76 million loss sequentially, and significantly surpassing the S&P Capital IQ consensus estimate of $34 million. Revenues totaled $2.154 billion — up 27% sequentially and 28% year over year — while consolidated net income reached $266 million, compared to a $52 million loss in Q1 and a $26 million loss in Q2 2023. Comparable EBITDA surged to $336 million, up from $150 million in Q1 and $125 million in Q2 2023, marking its strongest result since 2022.

Why did Alpek raise its 2026 comparable EBITDA guidance, and what is the new range?

Alpek raised its 2026 comparable EBITDA guidance from $450 million–$550 million to $750 million–$800 million due to the strong Q2 performance and the expectation that reference margins — particularly for PET, polypropylene, and EPS — will remain elevated, supported by favorable supply-demand dynamics including those stemming from the Middle East conflict and higher ocean freight rates.

Alpek posts Q2 beat on strong margins, raises 2026 guidance

Jul 25, 2026

Alpek SAB de CV reported a second-quarter net income beat of $183 million, raising its 2026 EBITDA guidance to $750-$800 million. Strong margins in PET, polypropylene, and EPS drove the results amid favorable supply-demand dynamics.

chemweek

2026-07-25

Alpek posts Q2 beat on strong margins, raises 2026 guidance

Alpek posts Q2 beat on strong margins, raises 2026 guidance

FAQ